Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Oct;85(19):7197-201.
doi: 10.1073/pnas.85.19.7197.

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

Affiliations

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

P A Wender et al. Proc Natl Acad Sci U S A. 1988 Oct.

Abstract

The bryostatins are macrocyclic lactones that represent an additional structural class of potent activators of protein kinase C. These marine animal biosynthetic products are of unusual interest because they induce only a subset of the biological responses induced by the phorbol esters. We have now determined the binding affinities of naturally occurring and semisynthetic bryostatins for protein kinase C by competition analysis with [26-3H]bryostatin 4 as the radioactive ligand. Esterification of the hydroxyl group at C26 caused dramatic loss of activity as did inversion of the asymmetric center at this position. In contrast, neither of the ester groups at C7 and C20 had a major influence on activity. Computer modeling of the phorbol esters, related diterpenes, and indole alkaloids suggested that the C20, C9, and C4 oxygens of phorbol represented critical elements of the phorbol ester pharmacophore. The C26 oxygen of the bryostatins, together with the C1 and C19 oxygens, gave an excellent spatial correlation with this model, with a root-mean-square deviation of 0.16 A (compared to 0.10-0.35 A among phorbol-related diterpenes). The extension of the phorbol ester pharmacophore model to the bryostatins and its agreement with the structure-activity relations for the bryostatin class of compounds provide additional support for the validity of the model.

PubMed Disclaimer

References

    1. Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 - PubMed
    1. Cancer Res. 1988 Jul 1;48(13):3702-8 - PubMed
    1. Carcinogenesis. 1984 Mar;5(3):315-8 - PubMed
    1. Nature. 1984 Apr 19-25;308(5961):693-8 - PubMed
    1. Biochim Biophys Acta. 1985 Sep 9;822(2):219-42 - PubMed

Publication types